@misc{indiciaec18a53885e4a,
  title = {RENOIR phase 3 rituximab-lenalidomide vs rituximab as maintenance treatment in relapsed/refractory follicular lymphoma.},
  author = {Barbara Botto and Carola Boccomini and Andrea Evangelista and Vittorio Ruggero Zilioli and Antonella Anastasia and Federica Cavallo and Francesco Merli and Manuela Zanni and Monica Tani and Annalisa Chiarenza and Anna Marina Liberati and Annarita Conconi and Chiara Rusconi and Alessia Bari and Ilaria Del Giudice and Gianluca Gaidano and Michele Spina and Nilla Maschio and Claudia Castellino and Delia Rota-Scalabrini and Benedetta Puccini and Annalisa Arcari and Sara Bigliardi and Giorgia Matta and Benedetta Bianchi and Donato Mannina and Dario Marino and Piero Galieni and Fabrizio Ciambelli and Gerardo Musuraca and Cristina Muzi and Chiara Bottelli and Elisa Genuardi and Erika Meli and Simone Ferrero and Stefano Luminari and Marco Ladetto and Giovannino Ciccone and Umberto Vitolo},
  year = {2026},
  doi = {10.1182/bloodadvances.2025018732},
  url = {https://pubmed.ncbi.nlm.nih.gov/42349017/},
  note = {Source identifier: 42349017}
}